CNBCLean R·
BioCryst is profitable. Now it wants to buy more rare disease drugs
Rare disease drug development is getting a boost from new funding models and a growing group of smaller biotech buyers.
Read at CNBC →
Rare disease drug development is getting a boost from new funding models and a growing group of smaller biotech buyers.
<iframe src="https://statesidedaily.com/embed/cluster/625e07a79e6940f46881d66023e8ba61a19c6813" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="BioCryst is profitable. Now it wants to buy more rare disease drugs"></iframe>